Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 4/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.54 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SHBG | P04278 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrocortisone SCHEMBL1332665 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL4111245 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184193 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5610354 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184192 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5139991 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL8366487 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL8360187 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL11169159 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL6461669 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 689 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260056216-A1 | ACUTE CORTICOID STRESS INDEX IN FISH | INNOLIPID AS (NO) | 2026-02-26 | — | — | US | claimed |
| US-20250205227-A1 | METHODS FOR ADMINISTERING CORTICOSTEROIDS | SPARROW PHARMACEUTICALS, INC. | 2025-06-26 | — | — | US | claimed |
| EP-4569333-A1 | ACUTE CORTICOID STRESS INDEX IN FISH | Innolipid, AS (NO) | 2025-06-18 | — | — | EP | claimed |
| EP-4562182-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-06-04 | — | — | EP | claimed |
| WO-2025096781-A1 | METHODS AND COMPOSITIONS FOR PROVIDING CUSTOMIZED SKIN REGIMENS | VIBRANT HOLDINGS, LLC (US) | 2025-05-08 | — | — | WO | claimed |
| EP-4537111-A2 | MULTI-OMICS ASSESSMENT | Prognomiq Inc (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119816897-A | Multiple study assessment | 普罗科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-5518999-A | SULFATED POLYSACCHARIDE-PEPTIDOGLYCAN | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-05-21 | — | — | US | claimed |
| EP-0632726-A4 | A METHOD FOR TREATING KAPOSI'S SARCOMA AND BLOCKING OR INHIBITING VASCULAR PERMEABILITY. | US ARMY (US) | 1995-11-29 | — | — | EP | claimed |
| EP-0632726-A1 | A METHOD FOR TREATING KAPOSI'S SARCOMA AND BLOCKING OR INHIBITING VASCULAR PERMEABILITY | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 1995-01-11 | — | — | EP | claimed |
| EP-0581803-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF A VARIETY OF DISORDERS UTILIZING ETIANATE AND AGONISTS THEREOF. | SINAI SCHOOL MEDICINE (US) | 1994-03-18 | — | — | EP | claimed |
| EP-0581803-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF A VARIETY OF DISORDERS UTILIZING ETIANATE AND AGONISTS THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1994-02-09 | — | — | EP | claimed |
| WO-1993012808-A1 | A METHOD FOR TREATING KAPOSI'S SARCOMA AND BLOCKING OR INHIBITING VASCULAR PERMEABILITY | NAKAMURA SHUJI (US) | 1993-07-08 | — | — | WO | claimed |
| WO-1992016235-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF A VARIETY OF DISORDERS UTILIZING ETIANATE AND AGONISTS THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1992-10-01 | — | — | WO | claimed |
| US-5021404-A | Angiostatic collagen modulators | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1991-06-04 | — | — | US | claimed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-4783402-A | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1988-11-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C1, NR3C2, SHBG | G6PD 461/4885CYP3A4 510/4885GABRA1 1805/4885 |
| US-20260056216-A1 | ACUTE CORTICOID STRESS INDEX IN FISH | CRH, HSD3B2, HSD3B1 | G6PD 632/4885CYP3A4 399/4885GABRA1 2907/4885 |
| US-20260137659-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | NR3C2, NR3C1, MC2R | G6PD 466/4885CYP3A4 527/4885GABRA1 1782/4885 |
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | G6PD 1366/4885CYP3A4 3050/4885GABRA1 2057/4885 |
| US-20250205227-A1 | METHODS FOR ADMINISTERING CORTICOSTEROIDS | HSD11B1, CYP21A2, HSD17B1 | G6PD 372/4885CYP3A4 75/4885GABRA1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.